ATE417064T1 - Hab18g/cd147, dessen antagonist und anwendung - Google Patents

Hab18g/cd147, dessen antagonist und anwendung

Info

Publication number
ATE417064T1
ATE417064T1 AT02734987T AT02734987T ATE417064T1 AT E417064 T1 ATE417064 T1 AT E417064T1 AT 02734987 T AT02734987 T AT 02734987T AT 02734987 T AT02734987 T AT 02734987T AT E417064 T1 ATE417064 T1 AT E417064T1
Authority
AT
Austria
Prior art keywords
hab18g
antisense
antisense nucleotide
peptide antagonists
expression plasmid
Prior art date
Application number
AT02734987T
Other languages
English (en)
Inventor
Zhinan Chen
Peng Shang
Yu Li
Airong Qian
Ping Zhu
Jinliang Xing
Original Assignee
Zhinan Chen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN 01115274 external-priority patent/CN1325907A/zh
Priority claimed from CN 01131735 external-priority patent/CN1186352C/zh
Application filed by Zhinan Chen filed Critical Zhinan Chen
Application granted granted Critical
Publication of ATE417064T1 publication Critical patent/ATE417064T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT02734987T 2001-05-25 2002-05-27 Hab18g/cd147, dessen antagonist und anwendung ATE417064T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN 01115274 CN1325907A (zh) 2001-05-25 2001-05-25 肝癌转移相关因子HAb18G及其反义RNA表达质粒载体PCI－asHAb18G
CN 01131735 CN1186352C (zh) 2001-09-28 2001-09-28 HAb18G/CD147肽类拮抗剂及其制备方法和用途

Publications (1)

Publication Number Publication Date
ATE417064T1 true ATE417064T1 (de) 2008-12-15

Family

ID=25740375

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02734987T ATE417064T1 (de) 2001-05-25 2002-05-27 Hab18g/cd147, dessen antagonist und anwendung

Country Status (6)

Country Link
US (1) US20050026841A1 (de)
EP (1) EP1403284B1 (de)
JP (1) JP2005504516A (de)
AT (1) ATE417064T1 (de)
DE (1) DE60230269D1 (de)
WO (1) WO2002094875A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1442203A (zh) * 2003-05-15 2003-09-17 陈志南 Sars冠状病毒和aids病毒（hiv－1）－cd147受体靶位拮抗剂
WO2005092381A1 (en) * 2004-03-25 2005-10-06 Centocor, Inc. Use of emmprin antagonists for the treatment of diseases associated with excessive angiogenesis
EP1796686A4 (de) * 2004-09-30 2008-05-14 Centocor Inc Emmprin-antagonisten und ihre verwendungen
JP4911950B2 (ja) * 2005-11-07 2012-04-04 晃 伊東 Ｍｍｐ−１の部分ペプチドを用いた癌浸潤・転移阻害薬
AU2009296937B2 (en) * 2008-09-29 2015-02-12 Centocor Ortho Biotech Inc. Anti-CD147 antibodies, methods, and uses
US9644019B2 (en) * 2010-12-02 2017-05-09 Carlos Zaragoza Sánchez Compounds for treating cardiac damage after ischaemia/reperfusion
WO2013150518A1 (en) 2012-04-01 2013-10-10 Rappaport Family Institute For Research In The Medical Sciences Extracellular matrix metalloproteinase inducer (emmprin) peptides and binding antibodies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002505097A (ja) * 1998-03-03 2002-02-19 アブジェニックス インク． 治療薬としてのｃｄ１４７結合分子

Also Published As

Publication number Publication date
US20050026841A1 (en) 2005-02-03
EP1403284B1 (de) 2008-12-10
DE60230269D1 (de) 2009-01-22
EP1403284A4 (de) 2005-12-28
JP2005504516A (ja) 2005-02-17
EP1403284A1 (de) 2004-03-31
WO2002094875A1 (fr) 2002-11-28

Similar Documents

Publication Publication Date Title
Sauane et al. MDA-7/IL-24: novel cancer growth suppressing and apoptosis inducing cytokine
Wuyts et al. Characterization of synthetic human granulocyte chemotactic protein 2: usage of chemokine receptors CXCR1 and CXCR2 and in vivo inflammatory properties
ES2381014T3 (es) Proteína quimérica inhibidora de la angiogénesis y el uso
Johns et al. Antiproliferative potencies of interferons on melanoma cell lines and xenografts: higher efficacy of interferon β
Hör et al. The T-cell lymphokine interleukin-26 targets epithelial cells through the interleukin-20 receptor 1 and interleukin-10 receptor 2 chains
KR101997757B1 (ko) 악액질 예방 또는 치료용 조성물
CN102481341B (zh) 蛋白原及其使用方法
US10093745B2 (en) Anti-CSPG4 fusions with interferon for the treatment of malignancy
JP2022095641A (ja) 条件的活性型ポリペプチド及びそれを生成する方法
Schmidt et al. Design and structural requirements of the potent and safe TLR-9 agonistic immunomodulator MGN1703
US9254309B2 (en) Use of multivalent synthetic ligands of surface nucleolin for treating cancer or inflammation
EA021867B1 (ru) Иммуномодулирующие полипептиды, полученные из il-2, и их применение для лечения рака и хронических инфекций
CN101663317A (zh) 胰高血糖素样蛋白-1受体glp-1r激动剂化合物
JP2011172572A (ja) 合成ケモカイン受容体リガンドおよびその使用方法
TWI375716B (en) Recombinant human interferon-like proteins
CN118451096A (zh) 异二聚体fc细胞因子及其用途
CN113179631A (zh) 通过临近使能反应疗法开发的共价蛋白质药物
BR112021008797A2 (pt) Polipeptídeos para o tratamento de síndromes de estresse, imunorreação e derrame
ATE417064T1 (de) Hab18g/cd147, dessen antagonist und anwendung
TWI800861B (zh) 包含抗lag-3抗體及il-2的融合蛋白及其用途
Adolf Structure and effects of interferon-gamma
EP4203992A1 (de) Onkolytische viren, die rekombinante transforming growth factor (tgf)-beta-monomere codieren, und deren verwendungen
US20090263354A1 (en) Compositions and siRNAs for inhibiting C/EBPbeta
Matheis et al. A bifunctional approach of immunostimulation and uPAR inhibition shows potent antitumor activity in melanoma
CN116970609A (zh) 用于清除hbv病毒的基因片段、其工具系统及应用

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties